Epigral Limited has notified the stock exchanges of a one-on-one meeting with Incred Research Services Pvt. Ltd., scheduled for August 20, 2026, in Ahmedabad. The intimation was made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has confirmed that no unpublished price sensitive information will be shared or discussed in the meeting.

Meeting details

The key details of the scheduled interaction are as follows:

Presentation availability

Epigral noted that the latest Earnings Presentation and Corporate Presentation that may be discussed during the meeting have already been placed on the company's website. The schedule of the meeting is subject to change due to exigencies on the part of institutional investors or the company.

Epigral Limited has informed stock exchanges that its management team will participate in the EMKAY Confluence 2026, an investor conference scheduled for August 12, 2026. The event will take place in Mumbai, providing investors with an opportunity to engage with company officials regarding business updates and strategic outlooks. This participation aims to enhance transparency and facilitate direct dialogue between the company and its stakeholders.

The disclosure was made on August 7, 2026, pursuant to Regulation 30 and Para (A) of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These regulations mandate timely disclosure of material events, including participation in investor conferences, to ensure equitable information dissemination to all market participants.

Event Details

The conference is organized by EMKAY Global Advisors, a leading investment banking firm. Epigral Limited’s presence at this forum underscores its commitment to maintaining regular communication with the investment community.

Regulatory Compliance

The intimation was submitted to both the National Stock Exchange of India Limited and BSE Limited. Gaurang Trivedi, Company Secretary & Compliance Officer of Epigral Limited, signed the disclosure. His membership number with the Institute of Company Secretaries of India is A22307.

Such disclosures are standard practice for listed entities in India, ensuring that all shareholders have equal access to information about upcoming investor interactions. The company did not disclose specific topics to be covered during the session, leaving the agenda open for general investor queries and corporate updates.